Definitive Radiotherapy in Salivary Gland Carcinoma of the Head and Neck

Purpose: This study was conducted to evaluate the treatment outcomes of definitive Radiotherapy (RT) for Salivary Gland Carcinoma (SGC). Material and methods:From January of 2010 till December of 2020, a total of 24 patients underwent definitive RT for SGCs arising in the head and neck region.The median Biologically Effective Dose (BED) prescribed to the GTV was 80.5 Gy 10 (79.1~84.9Gy 10 ) with dose-per-fraction of 1.8-2.2Gy.Elective neck irradiation of the clinically uninvolved lymph node was not a mandatory. Results:During the median follow-up duration of 31.9 months (range, 9.5-74.2months), 11 patients (45.8%) showed disease progression with locoregional progression being the most common treatment failure (n = 10; 41.7%).The 3-year Locoregional Control (LRC) and overall survival (OS) rates were 59.4% and 95.4%. Conclusion:The current study showed that definitive RT without ENI is a feasible strategy for inoperable SGCs.